Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer - Isomoto, Kohsuke; Haratani, Koji; Hayashi, Hidetoshi; Shimizu, Shigeki; Tomida, Shuta; Niwa, Takashi; Yokoyama, Toshihide; Fukuda, Yasushi; Chiba, Yasutaka; Kato, Ryoji; Tanizaki, Junko; Tanaka, Kaoru; et al. (Clinical cancer research, 2020)
Keywords: Adult; Aged; Aged, 80 and over; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - metabolism; Biomarkers, Tumor - immunology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - pathology; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Female; Humans; Immune Checkpoint Inhibitors - therapeutic use; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lymphocytes, Tumor-Infiltrating - immunology; Male; Middle Aged; Mutation; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology